This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| ARA-290 | Follistatin 344 | |
|---|---|---|
| Highest evidence tier on the page | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not FDA-approved; investigational (Phase 2 clinical stage); FDA orphan drug and fast track designations reported for sarcoidosis-associated small fiber neuropathy | Not approved in any form; only human data is from small, completed Phase 1/1-2 AAV gene-therapy trials for muscular dystrophy/myositis, not injectable protein use |
| Research area | Tissue repair and recovery | Growth hormone axis, Tissue repair and recovery |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C51H84N16O21 | Not reliably established |
| Molar mass | Approximately 1,257.32 g/mol | Not reliably established |
| CAS number | 1208243-50-8 | Not reliably established |
| Registered trials on this site | 1 in the tracker | 2 in the tracker |
| Furthest registered phase | Phase 2 | Phase 1 / Phase 2 |
| Trials currently active | 0 | 0 |
| Trial sponsors | Araim Pharmaceuticals, Inc. | Jerry R. Mendell, Nationwide Children's Hospital |
| What is not known | No currently active, later-phase registered clinical trial for cibinetide was identified as of this review; the most recent completed trial located (NCT02039687) finished in 2015, and it is unclear from public sources whether Araim Pharmaceuticals is continuing active clinical development. The FDA orphan drug and... | The largest open question for this entry is a category mismatch: essentially all human research on "follistatin-344" used AAV-vectored gene therapy causing a patient's own muscle to manufacture the protein locally over time, not a manufactured protein injected directly and repeatedly the way vendor "Follistatin... |
Full pages: ARA-290 and Follistatin 344. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
